176 related articles for article (PubMed ID: 21935651)
1. Is obesity a prognostic factor for acute myeloid leukemia outcome?
Lee HJ; Licht AS; Hyland AJ; Ford LA; Sait SN; Block AW; Barcos M; Baer MR; Wang ES; Wetzler M
Ann Hematol; 2012 Mar; 91(3):359-65. PubMed ID: 21935651
[TBL] [Abstract][Full Text] [Related]
2. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli S; Bérard E; Huguet F; Huynh A; Tavitian S; Vergez F; Dobbelstein S; Dastugue N; Mansat-De Mas V; Delabesse E; Duchayne E; Demur C; Sarry A; Lauwers-Cances V; Laurent G; Attal M; Récher C
Blood; 2013 Apr; 121(14):2618-26. PubMed ID: 23365464
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Appelbaum FR
Nat Rev Clin Oncol; 2010 Nov; 7(11):619-21. PubMed ID: 20981126
[No Abstract] [Full Text] [Related]
4. Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Ozcebe OI
J Natl Med Assoc; 2009 Mar; 101(3):270-2. PubMed ID: 19331261
[TBL] [Abstract][Full Text] [Related]
5. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
[TBL] [Abstract][Full Text] [Related]
8. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Garcia-Manero G
Best Pract Res Clin Haematol; 2012 Dec; 25(4):427-35. PubMed ID: 23200539
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Lee DH; Chung NG; Cho B; Kim HK; Kang HJ; Shin HY; Ahn HS; Yoo KH; Sung KW; Koo HH; Kook H; Hwang TJ; Im HJ; Seo JJ; Park HJ
J Korean Med Sci; 2010 Jan; 25(1):9-15. PubMed ID: 20052341
[TBL] [Abstract][Full Text] [Related]
10. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
12. Smoking adversely affects survival in acute myeloid leukemia patients.
Varadarajan R; Licht AS; Hyland AJ; Ford LA; Sait SN; Block AW; Barcos M; Baer MR; Wang ES; Wetzler M
Int J Cancer; 2012 Mar; 130(6):1451-8. PubMed ID: 21520043
[TBL] [Abstract][Full Text] [Related]
13. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Erba HP; Sayar H; Juckett M; Lahn M; Andre V; Callies S; Schmidt S; Kadam S; Brandt JT; Van Bockstaele D; Andreeff M
Invest New Drugs; 2013 Aug; 31(4):1023-34. PubMed ID: 23397500
[TBL] [Abstract][Full Text] [Related]
17. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani AS; Li H; Michaelis LC; Medeiros BC; Liedtke M; List AF; O'Dwyer K; Othus M; Erba HP; Appelbaum FR
Leuk Res; 2018 Apr; 67():17-20. PubMed ID: 29407182
[TBL] [Abstract][Full Text] [Related]
18. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
